Trial Profile
Phase I human safety testing of 18-methoxycoronaridine (18-MC) as a treatment for leishmaniasis.
Status:
Recruiting
Phase of Trial:
Phase I
Latest Information Update: 26 Sep 2014
Price :
$35
*
At a glance
- Drugs Zolunicant (Primary)
- Indications Leishmaniasis
- Focus Adverse reactions
- 26 Sep 2014 New trial record
- 23 Sep 2014 Interim results published in a Savant HWP media release.